Halberd Update on WatchDawg® PTSD Treatment
Portfolio Pulse from
Halberd Corporation has concluded an initial 10-person pilot study for its WatchDawg® PTSD treatment, targeting veterans with PTSD and potential suicidal ideation.
December 02, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halberd Corporation has completed an initial pilot study for its WatchDawg® PTSD treatment, which targets veterans with PTSD and potential suicidal ideation.
The completion of the pilot study is a significant milestone for Halberd's WatchDawg® PTSD treatment, potentially leading to further development and commercialization. This progress could positively impact HALB's stock price as it demonstrates advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100